Correction of the high blood viscosity syndrome by a mixture of Diquertin and Ascorbic Acid in vitro and in vivo.
Diquertin was shown to diminish blood viscosity, to decrease the aggregation of erythrocytes, and to increase their deformability using a model of the high blood viscosity syndrome in vitro. A mixture of Diquertin with Ascorbic Acid was more effective in improving rheological indicators of blood, then either Diquertin or Tanakan. On a model of chronic brain ischemia, which is accompanied by significant deterioration of the rheological properties of blood, it was shown that a therapy with a mixture of Diquertin and Ascorbic Acid decreases the expression of the high blood viscosity syndrome.
Plotnikov
M B
MB
Laboratory of Blood Circulation Pharmacology, Institution for Pharmacology, Scientific Center of Russian Academy of Medical Sciences, Tomsk, Russia.
Aliev
O I
OI
Maslov
M Ju
MJ
Vasiliev
A S
AS
Tjukavkina
N A
NA
D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001809:Blood Viscosity / Q000187:drug effects; D002545:Brain Ischemia / Q000188:drug therapy* / Q000473:pathology; D004359:Drug Therapy, Combination; D004903:Erythrocyte Aggregation / Q000187:drug effects; D005340:Fibrinogen / Q000187:drug effects; D008297:Male; D008517:Phytotherapy; D011794:Quercetin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar
D000975:Antioxidants; C473100:diquertin; D005340:Fibrinogen; D011794:Quercetin; D001205:Ascorbic Acid